title: Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target.
abstract: OBJECTIVE
  To systemically investigate, for a therapeutic protein with a circulating soluble target, how the interplay of target dynamics and drug pharmacokinetics defines the 'total' and 'free' drug and target temporal profiles.
  
  
  METHODS
  By extending the established rapid-binding target-mediated drug disposition (TMDD) pharmacokinetic model to circulating soluble targets, the temporal profiles of 'total' and 'free' drug and target were simulated with varying binding affinity (K(D)), target baseline (R(ss)), target turnover, and drug dose level. Two sets of published experimental data were compared with the simulated results.
  
  
  RESULTS
  Binding to a circulating soluble target could lead to a divergence of the 'free' drug from the 'total' drug. Simulations show this divergent magnitude determined by K(D) and R(ss), with the temporal profile being defined by target turnover and drug dose level. As divergence proceeds, starting at the distribution phase, 'free' drug would decline faster but eventually parallel 'total' drug at the terminal phase, giving rise to a steeper distribution phase and comparable terminal half-life, relative to the 'total' form. The model also allows for estimation of the dynamic change of 'total' and 'free' target in response to the treatment of a therapeutic protein drug, facilitating dose level and regimen design to achieve desired 'free' target suppression. Model predictions compared favorably with two sets of published experimental data.
  
  
  CONCLUSIONS
  Theoretical analyses identified key variables governing the different temporal profiles of 'total' and 'free' drug and target. The rapid-binding TMDD model reasonably captured the features of the interplay of drug pharmacokinetics and target dynamics for two reported cases.
authors: Department of Drug metabolism and Pharmacokinetics, WP75A-203, Merck Research Laboratories, West Point, Pennsylvania, 19486, USA. cuyue_tang@merck.com
authors: Cuyue
authors: C
authors: Tang
authors: Thomayant
authors: T
authors: Prueksaritanont
references: J Pharmacokinet Biopharm. 1999 Aug;27(4):397-420
references: 10826130
references: J Pharmacol Exp Ther. 2008 Aug;326(2):555-62
references: 18460643
references: Pharm Res. 2005 Oct;22(10):1589-96
references: 16180117
references: J Pharmacol Exp Ther. 2000 Feb;292(2):810-6
references: 10640322
references: Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3478-83
references: 17360669
references: J Pharmacokinet Pharmacodyn. 2009 Jun;36(3):199-219
references: 19434483
references: Alzheimer Dis Assoc Disord. 2010 Apr-Jun;24(2):198-203
references: 20505438
references: J Pharmacol Exp Ther. 1994 Jan;268(1):152-8
references: 8301552
references: AAPS J. 2010 Dec;12(4):646-57
references: 20737261
references: J Pharmacol Exp Ther. 2004 Jun;309(3):1085-92
references: 14872093
references: Clin Neuropharmacol. 2010 Mar-Apr;33(2):67-73
references: 20375655
references: J Pharmacol Exp Ther. 2005 Jun;313(3):1370-8
references: 15743932
references: J Pharmacokinet Pharmacodyn. 2009 Aug;36(4):341-51
references: 19578985
references: AAPS J. 2011 Mar;13(1):99-110
references: 21240643
references: Clin Pharmacol Ther. 2002 Apr;71(4):235-45
references: 11956506
references: Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18363-70
references: 18000042
references: J Pharm Sci. 2004 Nov;93(11):2645-68
references: 15389672
references: J Pharmacokinet Pharmacodyn. 2001 Dec;28(6):507-32
references: 11999290